Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 3/20 | 0.60 |
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.58 |
| ▸ | TAS1R1 | Q7RTX1 | 6/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.52 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.52 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12983696 | 0.82 | PIN1 (0.55) | TAS1R3TAS1R1HDAC3HDAC1HDAC2 | |
| SCHEMBL12983698 | 0.82 | PIN1 (0.55) | TAS1R3TAS1R1HDAC3HDAC1HDAC2 | |
| SCHEMBL11918871 | 0.80 | TAS1R3 (0.71) | TAS1R3TAS1R1 | |
| SCHEMBL4211750 | 0.80 | TAS1R3 (0.71) | TAS1R3TAS1R1 | |
| SCHEMBL4211753 | 0.80 | TAS1R3 (0.71) | TAS1R3TAS1R1 | |
| SCHEMBL5194508 | 0.80 | LNPEP (0.48) | CCKBRTAS1R3TAS1R1ERAP2LNPEP | |
| SCHEMBL25658905 | 0.80 | TAS1R3 (0.57) | TAS1R3TAS1R1HDAC1ERAP2LNPEP | |
| SCHEMBL25658941 | 0.79 | TAS1R3 (0.58) | TAS1R3TAS1R1HDAC3HDAC1HDAC2 | |
| SCHEMBL8235468 | 0.78 | CA1 (0.56) | TAS1R3TAS1R1ERAP2LNPEPERAP1 | |
| SCHEMBL25658900 | 0.77 | TAS1R3 (0.54) | TAS1R3TAS1R1ERAP2LNPEPERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190202810-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202810-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | HTRA1, ADCYAP1R1, HTRA2 | CCKBR 893/4885TAS1R3 1046/4885TAS1R1 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.